Chairman of the Board
Attorney, partner at Delphi law firm, LLM and MSc in Business and Economics
Born 1972 | Board member since 2014
Jens Kinnander has experience as a lawyer and as a corporate lawyer at some of Sweden’s largest companies, including Mannheimer Swartling and Sony Ericsson. Jens focuses in particular on the IT / Technology and Life Science sectors and his legal areas of specialization include intellectual property and IT law.
Other ongoing assignments: Chairman of the board of Kentima Holding AB (publ), deputy board member of PolarCool AB, chairman of the board at LUGI Tennis association
Consultant in medical device and pharma industries
Born 1950 | Board member since 2014
Hans Åke Henriksson has extensive experience from leading positions in global pharmaceutical and medical technology companies, focusing on business development and corporate governance. Hans has broad business experience from Asian markets, primarily Japan, China and South Korea.
Other ongoing assignments: Board member at HANOVA Healthcare Development AB.
Director of the Board
Born 1947 | Board member since 2014
Mats Forsman has a background in senior production and marketing roles at AstraZeneca, for more than 30 years. Mats also has extensive experience from the innovation system in Umeå through various roles within Innovationsbron Umeå AB and Umeå Universitet Holding AB, as well as through own enterprises.
Other ongoing assignments: Chairman of the Board at Inficure Bio AB and Airframe AB, and deputy board member of Forsman i Kråken AB.
Professor and Chief Physician in Oncology
Born 1953 | Board member since 2018
During 2012 -2018 Roger Henriksson was head of the Regional Cancer Center Stockholm / Gotland and in the county council of the healthcare in Stockholm County Council. He was recruited from the position as Head and chief physician at Radiumhemmet Karolinska University Hospital in Stockholm (2009-2012). He has been Vice President of Stratcan, a network of cancer research at Karolinska, and is a member of the Board of Cancer Center Karolinska. In addition, Roger Henriksson has also served as a senior advisor to AstraZeneca both at the international and national level and for many years been a member of the Regional Medicine Committee as well as advisors to a number of authorities in the cancer field.
Roger Henriksson has published more than 370 publications in highly rated journals such as Nature Genetics, JCO, New England Journal of Medicine, and Lancet Oncology and has received a number of scientific awards.